Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7111-7120 Newer>

Chemistry World January 27, 2011 Elinor Richards	Diet affects cholesterol drug Copper and zinc in the diet could impair the action of statin drugs, compounds prescribed to lower cholesterol, say US scientists.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool January 27, 2011 Brian Orelli	Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty.
The Motley Fool January 27, 2011 Sean Sun	Rising Star Buy: Amyris Biotechnologies The Dada Portfolio plunges into this innovative biotech contender.
The Motley Fool January 27, 2011 Brian Orelli	Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade.
The Motley Fool January 26, 2011 Brian Orelli	J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot.
The Motley Fool January 25, 2011 Brian Orelli	FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool January 25, 2011 Seth Jayson	Does This Mean Merck Will Burn You? Merck's year-over-year revenue grew 83.9%, and its AR grew 125.7%. That's a yellow flag.
The Motley Fool January 25, 2011 Eric Dutram	Tuesday's ETF to Watch: iShares Dow Jones U.S. Health Care Index Fund (IYH) The health-care sector has stagnated in recent weeks -- what does that mean for these ETFs?
<Older 7111-7120 Newer> Return to current articles.